- Home
- IPHA vs GLDG Comparison
IPHA vs GLDG Comparison
Compare IPHA & GLDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- GLDG
- Stock Information
- Founded
- IPHA 1999
- GLDG 2009
- Country
- IPHA France
- GLDG Canada
- Employees
- IPHA N/A
- GLDG N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- GLDG Precious Metals
- Sector
- IPHA Health Care
- GLDG Basic Materials
- Exchange
- IPHA Nasdaq
- GLDG Nasdaq
- Market Cap
- IPHA 160.1M
- GLDG 152.8M
- IPO Year
- IPHA 2019
- GLDG N/A
- Fundamental
- Price
- IPHA $1.82
- GLDG $0.72
- Analyst Decision
- IPHA Strong Buy
- GLDG Strong Buy
- Analyst Count
- IPHA 1
- GLDG 1
- Target Price
- IPHA $11.00
- GLDG $3.25
- AVG Volume (30 Days)
- IPHA 11.8K
- GLDG 609.8K
- Earning Date
- IPHA 03-27-2025
- GLDG 07-15-2025
- Dividend Yield
- IPHA N/A
- GLDG N/A
- EPS Growth
- IPHA N/A
- GLDG N/A
- EPS
- IPHA N/A
- GLDG N/A
- Revenue
- IPHA $20,831,349.00
- GLDG N/A
- Revenue This Year
- IPHA $209.83
- GLDG N/A
- Revenue Next Year
- IPHA $83.15
- GLDG N/A
- P/E Ratio
- IPHA N/A
- GLDG N/A
- Revenue Growth
- IPHA N/A
- GLDG N/A
- 52 Week Low
- IPHA $1.29
- GLDG $0.71
- 52 Week High
- IPHA $3.51
- GLDG $1.06
- Technical
- Relative Strength Index (RSI)
- IPHA 39.24
- GLDG 41.15
- Support Level
- IPHA $1.71
- GLDG $0.73
- Resistance Level
- IPHA $1.92
- GLDG $0.78
- Average True Range (ATR)
- IPHA 0.09
- GLDG 0.02
- MACD
- IPHA -0.00
- GLDG -0.00
- Stochastic Oscillator
- IPHA 37.93
- GLDG 7.36
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.